Rybelsus vs oral Wegovy: are they really the same drug?

What did @paige_km actually say?

Paige, who identifies as a pharmacist, was responding to a viewer question about the difference between Rybelsus and the newly developed oral Wegovy. Her core claim: both are oral semaglutide pills, and the only real difference is the indication. Rybelsus is approved for type 2 diabetes, while oral Wegovy is formulated for weight loss. She also floated the idea that this is "kind of a marketing ploy." She was upfront that she couldn't pin down the exact dosing differences. That honesty matters, because the dosing question turns out to be more significant than she implied.

Does the science back this up?

Partially. The active ingredient claim is accurate: both products contain semaglutide. But calling it "purely the indication" glosses over real pharmacological differences that affect how the drug works in your body.

Rybelsus uses a formulation called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) to improve absorption in the stomach. It tops out at a 14 mg daily dose. The oral Wegovy in development, studied under Novo Nordisk's OASIS trials, uses a different absorption-enhancing approach and is being evaluated at doses up to 50 mg daily. That is not a trivial difference. A paper by Knop et al. (2023, JAMA Internal Medicine) from the OASIS 1 trial reported that oral semaglutide 50 mg produced around 15.1% body weight reduction over 68 weeks in adults with obesity. Rybelsus at 14 mg was never designed or tested to achieve that kind of weight loss. Indication and dose are deeply connected here.

What did they get wrong (or right)?

She got the active ingredient right, and she was correct that the same molecule underlies both products. Credit where it is due. But the "purely the indication" framing is where things get shaky.

The dosing difference is not a footnote. It is likely the reason these are separate products. Regulatory agencies approve drugs based on the evidence package for a specific dose in a specific population. Rybelsus was approved at up to 14 mg based on the PIONEER trial program (Rodbard et al., 2019, Diabetes Care). Oral Wegovy is being developed at doses 3-4 times higher, with a distinct efficacy and safety profile for a different patient population. Calling this primarily a marketing distinction undersells the clinical engineering involved in getting higher doses of semaglutide to absorb reliably through an oral route. It is not nothing.

Her uncertainty about dosing strengths is understandable given where oral Wegovy sits in the regulatory pipeline, but that gap in the explanation leaves viewers with a misleading picture of why these are actually two different products.

What should you actually know?

If you are a patient trying to make sense of the semaglutide landscape, here is what is actually useful. Rybelsus is an approved, available drug for type 2 diabetes. It lowers blood sugar and can produce modest weight loss as a secondary effect, but it was not built or dosed for obesity treatment.

Oral Wegovy, as of early 2025, is still working through regulatory review. The FDA accepted Novo Nordisk's NDA filing for oral semaglutide 50 mg for obesity in late 2024. Until it is approved and on pharmacy shelves, it is not an option patients can access through standard channels.

The "marketing ploy" framing deserves pushback. Pharmaceutical companies do use indication-based branding, and that is fair to note. But in this case, there is a real pharmacological and clinical story behind the two products. Patients asking their pharmacist about switching from Rybelsus to oral Wegovy for weight loss should know these are not interchangeable, the doses are different, the approval status is different, and the evidence base is different.

• Do not assume Rybelsus will produce the same weight loss as oral Wegovy based on this video.
• Ask your prescriber about your specific indication before making any changes.
• Oral Wegovy is not yet widely available as of early 2025.

Bottom line

Paige gave viewers a reasonable starting framework, and her credential transparency is appropriate for the platform. But the "purely the indication" claim oversimplifies a genuinely complex story. The dose difference is real, the clinical evidence is distinct, and patients deserve to know that before assuming these products are essentially the same pill with different branding.